The case for & against
Bull & Bear analysis
Bearish
Mabvax Therapeutics Holdings Inc. (OTC: MBVX) was a clinical-stage biotechnology company focused on developing therapeutic and diagnostic products for cancer treatment. However, the company appears to have ceased operations and is no longer active, according to multiple sources, including BioCentury and Fintel. Previously based in San Diego, CA, Mabvax's operations revolved around antibody therapies to target cancer cells, but it has since been categorized as "out of business," indicating a potential lack of innovation or developmental progress in its field, contributing to its poor market viability.
Bull says
- ↑No active pipeline or operations since 2018
- ↑Market cap ≈ $216.9K leaves no upside
Bear says
- ↓Officially “Out of Business” per Fintel and BioCentury
- ↓Market cap ≈ $216.9K reflects negligible liquidity
- ↓No press releases or updates since Nov 28, 2018
- ↓Zero revenue and inactive pipeline offer no recovery
- ↓High delisting risk amplifies potential losses
- ↓No moat or competitive edge; company unlikely to revive